Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada.
Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.
JAMA Intern Med. 2024 May 1;184(5):474-482. doi: 10.1001/jamainternmed.2023.8232.
Central venous catheters (CVCs) are commonly used but are associated with complications. Quantifying complication rates is essential for guiding CVC utilization decisions.
To summarize current rates of CVC-associated complications.
MEDLINE, Embase, CINAHL, and CENTRAL databases were searched for observational studies and randomized clinical trials published between 2015 to 2023.
This study included English-language observational studies and randomized clinical trials of adult patients that reported complication rates of short-term centrally inserted CVCs and data for 1 or more outcomes of interest. Studies that evaluated long-term intravascular devices, focused on dialysis catheters not typically used for medication administration, or studied catheters placed by radiologists were excluded.
Two reviewers independently extracted data and assessed risk of bias. Bayesian random-effects meta-analysis was applied to summarize event rates. Rates of placement complications (events/1000 catheters with 95% credible interval [CrI]) and use complications (events/1000 catheter-days with 95% CrI) were estimated.
Ten prespecified complications associated with CVC placement (placement failure, arterial puncture, arterial cannulation, pneumothorax, bleeding events requiring action, nerve injury, arteriovenous fistula, cardiac tamponade, arrhythmia, and delay of ≥1 hour in vasopressor administration) and 5 prespecified complications associated with CVC use (malfunction, infection, deep vein thrombosis [DVT], thrombophlebitis, and venous stenosis) were assessed. The composite of 4 serious complications (arterial cannulation, pneumothorax, infection, or DVT) after CVC exposure for 3 days was also assessed.
Of 11 722 screened studies, 130 were included in the analyses. Seven of 15 prespecified complications were meta-analyzed. Placement failure occurred at 20.4 (95% CrI, 10.9-34.4) events per 1000 catheters placed. Other rates of CVC placement complications (per 1000 catheters) were arterial canulation (2.8; 95% CrI, 0.1-10), arterial puncture (16.2; 95% CrI, 11.5-22), and pneumothorax (4.4; 95% CrI, 2.7-6.5). Rates of CVC use complications (per 1000 catheter-days) were malfunction (5.5; 95% CrI, 0.6-38), infection (4.8; 95% CrI, 3.4-6.6), and DVT (2.7; 95% CrI, 1.0-6.2). It was estimated that 30.2 (95% CrI, 21.8-43.0) in 1000 patients with a CVC for 3 days would develop 1 or more serious complication (arterial cannulation, pneumothorax, infection, or DVT). Use of ultrasonography was associated with lower rates of arterial puncture (risk ratio [RR], 0.20; 95% CrI, 0.09-0.44; 13.5 events vs 68.8 events/1000 catheters) and pneumothorax (RR, 0.25; 95% CrI, 0.08-0.80; 2.4 events vs 9.9 events/1000 catheters).
Approximately 3% of CVC placements were associated with major complications. Use of ultrasonography guidance may reduce specific risks including arterial puncture and pneumothorax.
重要性:中心静脉导管(CVC)是一种常用的医疗器械,但与多种并发症相关。量化并发症的发生率对于指导 CVC 使用决策至关重要。
目的:总结 CVC 相关并发症的现有发生率。
数据来源:对 2015 年至 2023 年期间发表的观察性研究和随机临床试验进行了 MEDLINE、Embase、CINAHL 和 CENTRAL 数据库的检索。
研究选择:本研究纳入了报告短期中心插入 CVC 并发症发生率以及 1 个或多个感兴趣结局数据的英语语言观察性研究和随机临床试验。排除了评估长期血管内设备、主要关注通常不用于药物输注的透析导管或研究放射科医生放置的导管的研究。
数据提取和综合:两名审查员独立提取数据并评估偏倚风险。应用贝叶斯随机效应荟萃分析总结事件发生率。估计了放置并发症(每 1000 个导管发生的事件数/1000 导管天,95%可信区间[CrI])和使用并发症(每 1000 导管天发生的事件数/1000 导管天,95%CrI)的发生率。
主要结局和测量:评估了与 CVC 放置相关的 10 种预先指定的并发症(放置失败、动脉穿刺、动脉插管、气胸、需要采取行动的出血事件、神经损伤、动静脉瘘、心脏压塞、心律失常、血管加压药物治疗延迟 1 小时以上)和与 CVC 使用相关的 5 种预先指定的并发症(故障、感染、深静脉血栓形成[DVT]、血栓性静脉炎和静脉狭窄)。还评估了在 CVC 暴露 3 天后,4 种严重并发症(动脉插管、气胸、感染或 DVT)的复合发生率。
结果:在筛选的 11722 项研究中,有 130 项研究纳入了分析。7 种预先指定的并发症进行了荟萃分析。每放置 1000 个导管发生放置失败的事件数为 20.4(95%CrI,10.9-34.4)。其他 CVC 放置并发症的发生率(每 1000 个导管)分别为动脉插管(2.8;95%CrI,0.1-10)、动脉穿刺(16.2;95%CrI,11.5-22)和气胸(4.4;95%CrI,2.7-6.5)。CVC 使用并发症的发生率(每 1000 个导管天)分别为故障(5.5;95%CrI,0.6-38)、感染(4.8;95%CrI,3.4-6.6)和 DVT(2.7;95%CrI,1.0-6.2)。据估计,在接受 CVC 治疗 3 天的 1000 例患者中,有 30.2 例(95%CrI,21.8-43.0)会发生 1 种或多种严重并发症(动脉插管、气胸、感染或 DVT)。使用超声检查与较低的动脉穿刺发生率相关(风险比[RR],0.20;95%CrI,0.09-0.44;每 1000 个导管发生 13.5 次 vs 每 1000 个导管发生 68.8 次)和气胸发生率(RR,0.25;95%CrI,0.08-0.80;每 1000 个导管发生 2.4 次 vs 每 1000 个导管发生 9.9 次)。
结论和意义:大约 3%的 CVC 置管与严重并发症相关。使用超声引导可能会降低特定风险,包括动脉穿刺和气胸。